Back to results
US 9,040,241 B2Granted
Genetic markers of mental illness
AssigneeSuregene, LLC
InventorsMark David Brennan, Timothy Lynn Ramsey
Life of this patent
Estimating the term…
Abstract
This invention relates to genetic markers of mental illness, e.g., schizophrenia (SZ), and methods of use thereof.
Claims30
A method of treating a human subject having schizophrenia (SZ), the method comprising:
- selecting a human subject having SZ;
- performing an assay to determine an ankyrin-3 (ANK3) haplotype for the selected subject, wherein the ANK3 haplotype comprises an allele of single nucleotide polymorphism rs1551213;
- identifying a selected subject having a T allele at rs1551213 as more likely to have a negative side effect in response to risperidone compared to a subject not having a T allele at rs1551213, or identifying a selected subject not having a T allele at rs1551213 as less likely to have a negative side effect in response to risperidone compared to a subject having a T allele at rs1551213;
- and
- administering a treatment not comprising risperidone to a selected subject identified as having an T allele at rs1551213 or administering a treatment comprising risperidone to a selected subject identified as not having a T allele at rs1551213.
2 more elements
A method of treating a human subject having schizophrenia (SZ), the method comprising:
- selecting a human subject having SZ;
- performing an assay to determine an ankyrin-3 (ANK3) haplotype for the selected subject, wherein the ANK3 haplotype comprises an allele of single nucleotide polymorphism rs1551213;
- identifying a selected subject having a T allele at rs1551213 or identifying a selected subject not having a T allele at rs1551213;
- and
- administering a treatment not comprising risperidone to a selected subject identified as having a T allele at rs1551213, or administering a treatment comprising risperidone to a selected subject not having a T allele at rs1551213.
2 more elements
A method of treating a human subject having schizophrenia (SZ), the method comprising:
- selecting a human subject having-SZ;
- performing an assay to determine an ankyrin-3 (ANK3) haplotype for the selected human subject, wherein the ANK3 haplotype comprises an allele of single nucleotide polymorphism rs1551213;
- identifying a selected subject having a T allele at rs1551213 or identifying a selected subject not having a T allele at rs1551213;
- selecting a treatment not comprising risperidone for a selected subject identified as having a T allele at rs1551213, or selecting a treatment comprising risperidone for a selected subject identified as not having a T allele at rs17785419;
- and
- administering a treatment not comprising risperidone to a selected subject identified as having a T allele at rs1551213, or administering a treatment comprising risperidone to a selected subject identified as not having a T allele at rs1551213.
3 more elements
Dependencies are inferred from the claim text.